Venetoclax + ethinyl estradiol/levonorgestrel
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematologic Malignancies
Conditions
Hematologic Malignancies
Trial Timeline
Jul 30, 2019 → Mar 21, 2026
NCT ID
NCT03557619About Venetoclax + ethinyl estradiol/levonorgestrel
Venetoclax + ethinyl estradiol/levonorgestrel is a phase 1 stage product being developed by AbbVie for Hematologic Malignancies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03557619. Target conditions include Hematologic Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03557619 | Phase 1 | Recruiting |
Competing Products
20 competing products in Hematologic Malignancies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 52 |
| RLYB116 for Injection | Rallybio | Phase 1 | 25 |
| DS3790a + Combination drug + Combination drug | Daiichi Sankyo | Phase 1/2 | 41 |
| Isavuconazole | Astellas Pharma | Phase 2 | 52 |
| isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral | Astellas Pharma | Phase 1 | 33 |
| DSP-5336 + [14C]-DSP-5336 | Sumitomo Pharma | Phase 1 | 33 |
| BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib | Sumitomo Pharma | Phase 1 | 33 |
| ABT-888 + Temozolomide | AbbVie | Phase 1 | 33 |
| ABBV-101 | AbbVie | Phase 1 | 33 |
| elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection | AbbVie | Phase 2 | 52 |
| Capivasertib + Rabeprazole | AstraZeneca | Phase 1 | 33 |
| AZD9829 + AZD9829 | AstraZeneca | Phase 1/2 | 41 |
| ridaforolimus | Merck | Phase 2 | 52 |
| Pembrolizumab/vibostolimab coformulation | Merck | Phase 2 | 52 |
| Nemtabrutinib | Merck | Phase 1 | 33 |
| Ondansetron + Aprepitant | Merck | Phase 2 | 52 |
| Nemtabrutinib | Merck | Phase 2 | 52 |
| ARQ 621 | Merck | Phase 1 | 33 |
| Nemtabrutinib | Merck | Phase 1 | 33 |
| Pelabresib | Novartis | Phase 3 | 77 |